EWTX · Edgewise Therapeutics, Inc. · Executive Compensation
$39.91
-1.27 (-3.07%)
At close · Nov 20
Return incl. dividend (before tax)
Market Cap
$4.37B
Shares
109.48M
Volume · Nov 20
1.19M
Avg daily vol (3M)
1.53M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
No Compensation Data
No Summary Compensation Table has been imported from this company's proxy statements yet.
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Christopher Martin | Class I director | Appointed | 2025-11-20 |
|
Michael Carruthers
“Mr. Carruthers' decision was not the result of any disagreement with the Company.”
|
Chief Financial Officer | Retired | 2025-11-10 |
| Michael Nofi | Chief Financial Officer | Appointed | 2025-11-10 |
| Behrad Derakhshan | Chief Operating Officer | Appointed | 2025-01-22 |
| Arlene Morris | Class I director | Appointed | 2024-05-07 |
|
Kenneth Harrison, Ph.D.
“Dr. Harrison’s resignation was not the result of any disagreement with management or the Board.”
|
Board | Resigned | 2023-06-22 |
| Dr. Jonathan Fox | Class III director | Appointed | 2023-03-06 |
Leadership
- Kevin Koch CEO, Board Member
- Michael P. Nofi CFO
- R. Michael Carruthers CFO
- Behrad Derakhshan COO
- Alan Russell Board Member
- Christopher Martin Board Member
- Dr. Jonathan Fox Board Member
- Jonathan Root Board Member
- Laura Brege Board Member
Key facts
CIK
1710072
CUSIP
28036F105
13F (30d)
260 filings
237 filers
Visit website
Investor relations